<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23734218</article-id><article-id pub-id-type="pmc">3666971</article-id><article-id pub-id-type="publisher-id">PONE-D-13-01616</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0064774</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Anatomy and Physiology</subject><subj-group><subject>Cardiovascular System</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Anatomy and Physiology</subject><subj-group><subject>Cardiovascular System</subject><subj-group><subject>Cardiovascular Anatomy</subject></subj-group></subj-group></subj-group><subj-group><subject>Cardiovascular</subject><subj-group><subject>Angina</subject><subject>Atherosclerosis</subject><subject>Cardiovascular Imaging</subject><subject>Coronary Artery Disease</subject><subject>Heart Failure</subject><subject>Interventional Cardiology</subject><subject>Vascular Biology</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>The Association between Progression of Atherosclerosis and the Methylated Amino Acids Asymmetric Dimethylarginine and Trimethyllysine</article-title><alt-title alt-title-type="running-head">ADMA, TML and Progression of CAD</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>L&#x000f8;land</surname><given-names>Kjetil H.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bleie</surname><given-names>&#x000d8;yvind</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Borgeraas</surname><given-names>Heidi</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Strand</surname><given-names>Elin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ueland</surname><given-names>Per M.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Svardal</surname><given-names>Asbj&#x000f8;rn</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nordrehaug</surname><given-names>Jan E.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nyg&#x000e5;rd</surname><given-names>Ottar</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Clinical Science, University of Bergen, Bergen, Norway</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Heart Disease, Haukeland University Hospital, Bergen, Norway</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Morbid Obesity Centre, Vestfold Hospital Trust, T&#x000f8;nsberg, Norway</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Gong</surname><given-names>Yan</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>College of Pharmacy, University of Florida, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>kjetil.loland@gmail.com</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The main sponsors were nonprofit organizations with no participating role in the trial. Alpharma Inc provided the study capsules, generated the randomization sequence, and concealed the randomization code free of charge and rendered a limited grant to finance the initial phase of the trial. However, Alpharma Inc had no role in the design or implementation of the trial, had no access to study data, and did not participate in data analysis or interpretation or in the preparation, review, or approval of the manuscript. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: ON JEN PMU OB. Performed the experiments: ON OB KHL ES AS. Analyzed the data: KHL HB OB ES PMU AS JEN ON. Contributed reagents/materials/analysis tools: ES AS. Wrote the paper: KHL HB OB ON PMU.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>29</day><month>5</month><year>2013</year></pub-date><volume>8</volume><issue>5</issue><elocation-id>e64774</elocation-id><history><date date-type="received"><day>7</day><month>1</month><year>2013</year></date><date date-type="accepted"><day>17</day><month>4</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 L&#x000f8;land et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>L&#x000f8;land et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>We previously showed that treatment with folic acid (FA)/B<sub>12</sub> was associated with more rapid progression of coronary artery disease (CAD). High doses of FA may induce methylation by increasing the availability of S-adenosyl-methionine (SAM). Asymmetric dimethylarginine (ADMA) and trimethyllysine (TML) are both produced through proteolytic release following post-translational SAM&#x02013;dependent methylation of precursor amino acid. ADMA has previously been associated with CAD. We investigated if plasma levels of ADMA and TML were associated with progression of CAD as measured by quantitative coronary angiography (QCA).</p></sec><sec><title>Methods</title><p>183 patients from the Western Norway B Vitamin Intervention Trial (WENBIT) undergoing percutaneous coronary intervention (PCI) were randomized to daily treatment with 0.8 mg FA/0.4 mg B<sub>12</sub> with and without 40 mg B<sub>6</sub>, B<sub>6</sub> alone or placebo. Coronary angiograms and plasma samples of ADMA and TML were obtained at both baseline and follow-up (median 10.5 months). The primary end-point was progression of CAD as measured by diameter stenosis (DS) evaluated by linear quantile mixed models.</p></sec><sec><title>Results</title><p>A total of 309 coronary lesions not treated with PCI were identified. At follow-up median (95% CI) DS increased by 18.35 (5.22&#x02013;31.49) percentage points per &#x000b5;mol/L ADMA increase (p-value 0.006) and 2.47 (0.37&#x02013;4.58) percentage points per &#x000b5;mol/L TML increase (p-value 0.021) in multivariate modeling. Treatment with FA/B<sub>12</sub> (&#x000b1;B<sub>6</sub>) was not associated with ADMA or TML levels.</p></sec><sec><title>Conclusion</title><p>In patients with established CAD, baseline ADMA and TML was associated with angiographic progression of CAD. However, neither ADMA nor TML levels were altered by treatment with FA/B<sub>12</sub> (&#x000b1;B<sub>6</sub>).</p></sec><sec><title>Trial Registration</title><p>Controlled-Trials.com <ext-link ext-link-type="uri" xlink:href="http://controlledtrials.com/ct2/show/NCT00354081">NCT00354081</ext-link>
</p></sec></abstract><funding-group><funding-statement>The study was funded by the Norwegian Foundation for Health and Rehabilitation, the Norwegian Heart and Lung Patient Organization, the Norwegian Ministry of Health and Care Services, the Western Norway Regional Health Authority, the Department of Heart Disease at Haukeland University Hospital, the Foundation to Promote Research Into Functional Vitamin B12 Deficiency, Bergen, Norway, and Alpharma Inc, Copenhagen, Denmark. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Hyperhomocysteinemia is a significant risk factor for coronary artery disease (CAD) in epidemiological studies. However, several large-scale clinical trials with homocysteine-lowering B-vitamins have repeatedly demonstrated no clinical benefit of the intervention. <xref rid="pone.0064774-Ebbing1" ref-type="bibr">[1]</xref>&#x02013;<xref rid="pone.0064774-Celik1" ref-type="bibr">[3]</xref> On the contrary, pooled analyses suggest increased cardiovascular mortality associated with B-vitamin treatment in certain sub-groups <xref rid="pone.0064774-Ebbing2" ref-type="bibr">[2]</xref> as well as increased cancer incidence and all-cause mortality. <xref rid="pone.0064774-Ebbing3" ref-type="bibr">[4]</xref> We have previously shown that a sub-group of patients with established CAD had a more rapid progression of sub-clinical atherosclerosis as measured by quantitative coronary angiography (QCA), when receiving 0.8 mg folic acid (FA) and 0.4 mg vitamin B<sub>12</sub> daily. <xref rid="pone.0064774-Lland1" ref-type="bibr">[5]</xref> FA and vitamin B<sub>12</sub> supplementation promotes remethylation of homocysteine to methionine and subsequently increases S-adenosyl-methionine (SAM), which is the main methyl donor in cellular transmethylation reactions. <xref rid="pone.0064774-Handy1" ref-type="bibr">[6]</xref>.</p><p>A growing body of evidence has shown that both global and site-specific hypo- and hypermethylation of DNA and histones are associated with cardiovascular disease (CVD). <xref rid="pone.0064774-Handy1" ref-type="bibr">[6]</xref> High doses of FA induce aberrant DNA methylation in some <xref rid="pone.0064774-Charles1" ref-type="bibr">[7]</xref> but not all studies. <xref rid="pone.0064774-Jung1" ref-type="bibr">[8]</xref> It has been speculated that the lack of cardiovascular protective effect of homocysteine-lowering FA supplementation is due to a simultaneously increased methylation potential and subsequent epigenetic alterations of gene expression by folate. <xref rid="pone.0064774-Loscalzo1" ref-type="bibr">[9]</xref> Histone methylation is limited to the &#x003b5;-amino groups of amino acid residues in the form of mono-, di- or trimethylation, <xref rid="pone.0064774-Handy1" ref-type="bibr">[6]</xref> and only two amino acids in histones undergo methylation, i.e. arginine and lysine. <xref rid="pone.0064774-Cheung1" ref-type="bibr">[10]</xref>.</p><p>Asymmetric dimethylarginine (ADMA), a product of proteolytic degradation of methylated proteins such as histones, is a well-known inhibitor of nitric oxide synthase (NOS) and has been associated with endothelial dysfunction and CVD. <xref rid="pone.0064774-Cooke1" ref-type="bibr">[11]</xref>&#x02013;<xref rid="pone.0064774-Bger1" ref-type="bibr">[14]</xref> ADMA levels have not, to our knowledge, been linked to global methylation status. 6-N-trimethyllysine (TML), a precursor in carnitine synthesis, <xref rid="pone.0064774-Bremer1" ref-type="bibr">[15]</xref>, <xref rid="pone.0064774-Strijbis1" ref-type="bibr">[16]</xref> is another methylated amino acid which is produced through the lysosomal or proteasomal degradation of proteins such as histones containing methylated amino acids residues, specifically trimethylated lysine. <xref rid="pone.0064774-Strijbis1" ref-type="bibr">[16]</xref>.</p><p>We investigated whether ADMA and TML could serve as predictive markers of progression of CAD as measured by QCA and if treatment with FA-vitamin B<sub>12</sub> is related to ADMA or TML levels.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study Design and Patient Population</title><p>The current study included patients who participated in the Western Norway B Vitamin Intervention Trial (WENBIT). WENBIT was a double-blinded, placebo-controlled, two-centre trial conducted among 3090 adult patients (20.5% women) having undergone coronary angiography for suspected CAD. Details, inclusion and exclusion criteria, and the main results of the trial have been described previously <xref rid="pone.0064774-Ebbing1" ref-type="bibr">[1]</xref> In order to simultaneously evaluate the effect of FA/vitamin B<sub>12</sub> and vitamin B<sub>6</sub>, patients were randomly assigned into 4 groups, using 2 by 2 factorial design, to daily receiving an oral capsule with one of the following compositions: 1) FA 0.8 mg, vitamin B<sub>12</sub> (cyanocobalamin) 0.4 mg and vitamin B<sub>6</sub> (pyridoxine) 40 mg, or 2) FA plus vitamin B<sub>12</sub>, or 3) vitamin B<sub>6</sub>, or 4) placebo. In this study we evaluated the effect of FA/vitamin B<sub>12</sub> on plasma levels of ADMA and TML. Intervention groups 1) and 2) were thus compared to 3) and 4) in the subsequent analyses.</p><p>In the current sub-study, patients at high risk of procedural complications, or those presenting with a baseline coronary anatomy of such a nature that re-angiography probably would prove unsuccessful, were also excluded. Further exclusion criteria were baseline and/or follow-up coronary angiograms considered unsuitable for quantitative analysis.</p><p>At Haukeland University Hospital a total of 570 patients underwent percutaneous coronary intervention (PCI) following the baseline angiography during the sub-study inclusion time period and were eligible for re-angiography, of which 371 (65%) underwent re-angiography as previously described. <xref rid="pone.0064774-Lland1" ref-type="bibr">[5]</xref> A total of 23 (6%) participants were excluded from the analysis due to technically inadequate angiograms and 165 (47%) participants did not fulfill QCA lesion criteria. We included 183 patients with adequate serial QCA data who had at least one qualifying lesion, resulting in a total of 309 coronary lesions for analyses.</p></sec><sec id="s2b"><title>Ethics Statement</title><p>All clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from all WENBIT participants, and an additional written informed consent was collected from patients scheduled for re-angiography. Both WENBIT and the current sub-study were approved by the Regional Committee for Medical and Health Research Ethics (Regional Ethics Committee [REC] West/Regional Etisk Komit&#x000e9; [REK] vest, which is the institutional review board available at <ext-link ext-link-type="uri" xlink:href="http://helseforskning.etikkom.no">http://helseforskning.etikkom.no</ext-link>), the Norwegian Medicines Agency (Legemiddelverket) and by the Data Inspectorate (Datatilsynet). WENBIT was registered with ClinicalTrials.gov with identifier NCT00354081 and URL <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT00354081">http://www.clinicaltrials.gov/ct2/show/NCT00354081</ext-link>. WENBIT was a two-centre study conducted at Haukeland University Hospital, Bergen, and Stavanger University Hospital, Stavanger, both located in western Norway. All clinical research was conducted in Norway and was subject to Norwegian law.</p></sec><sec id="s2c"><title>Quantitative Coronary Angiography</title><p>Both baseline and follow-up coronary angiograms were analysed using QCA by two trained technicians blinded to the treatment regimen and supervised by an experienced interventional cardiologist. A total of 16 coronary artery segments were evaluated in all patients; i.e. 15 segments as per the American Heart Association standardization criteria, <xref rid="pone.0064774-Austen1" ref-type="bibr">[17]</xref> plus the right atrioventricular branch. Eligible lesions for analysis had a reference diameter &#x02265;2 mm, diameter reduction of &#x02265;30% at either baseline or follow-up, and were adequately visualized at similar projections at both procedures. The analysed segment had not been treated with PCI. Cases of disagreement between the observers, about eligibility of a certain lesion, were subject to reanalyses by both observers. Following all QCA procedures, segments from both observers were compared to ensure equality concerning accurate numbering of segments, the correct angiogram analysed, and the actual stenosis portrayed.</p><p>Lesions were analysed using digitalized QCA (Quantcor QCA [CAAS II V 5.0], Pie Medical Imaging, the Netherlands). An end-diastolic frame showing the stenosis without foreshortening or vessel overlap, and free of intra-coronary wires, was selected. If the stenosis differed in severity in different projections, the projection demonstrating the most severe stenosis was subject to analysis. The contrast-filled tip of the catheter was used for calibration, and computer-defined obstruction analysis without manual contour correction was used where applicable. However, ostial stenoses required the use of manually-defined obstruction analysis (user-defined reference vessel diameter and stenosis length), while branched artery segment required manual correction of vessel contour.</p></sec><sec id="s2d"><title>Follow-up and End-point</title><p>The primary measure for each selected lesion was diameter stenosis (DS) <xref rid="pone.0064774-Azen1" ref-type="bibr">[18]</xref>, <xref rid="pone.0064774-Mack1" ref-type="bibr">[19]</xref> in percentages, measured as continuous variables and defined as the mean of the values measured separately by two different observers.</p><p>When all baseline and follow-up lesions had been analysed by both observers, the inter-observer difference in DS was calculated. The 10% of lesions with the largest difference were subject to re-analysis.</p><p>The primary angiographic end-point of the study was defined as DS measured at follow-up, while baseline values were used for adjustment. I.e. change in DS was the <italic>de facto</italic> end-point.</p></sec><sec id="s2e"><title>Blood Samples</title><p>Blood samples were collected at baseline and at the re-angiography. Routine blood analyses such as hematologic parameters, renal function markers and lipid-related factors were analysed in fresh samples at the Laboratory of Clinical Biochemistry, Haukeland University Hospital, by standard methods, all blinded to study end-points and randomization. Blood samples for measurements of ADMA, B vitamins and associated compounds were analysed at the laboratory of Bevital AS (<ext-link ext-link-type="uri" xlink:href="http://www.bevital.no">www.bevital.no</ext-link>), Bergen, Norway using methods previously described. <xref rid="pone.0064774-Bleie1" ref-type="bibr">[20]</xref> Plasma TML, free carnitine and &#x003b3;-butyrobetaine were analysed using MS/MS as described previously <xref rid="pone.0064774-Bjrndal1" ref-type="bibr">[21]</xref> with some modifications of the high-performance liquid chromatography (HPLC) conditions. Estimation of glomerular filtration (eGFR) rate was done using the simplified MDRD-equation. <xref rid="pone.0064774-Levey1" ref-type="bibr">[22]</xref>.</p></sec><sec id="s2f"><title>Statistical Analysis</title><p>Analyses were conducted according to the intention-to-treat principle. Continuous variables are reported as means &#x000b1; SD or as median (interquartile range) where appropriate. Categorical variables are presented as numbers (percentages).</p><p>Differences between intervention groups in continuous variables were analysed using Student&#x02019;s <italic>t</italic>-test or Mann Whitney U-test. Differences in categorical variables were analysed by chi-square test or Fisher&#x02019;s exact test. Inter-observer reliability were assessed on QCA measurements by calculating the average measure intra-class coefficient <xref rid="pone.0064774-Rothwell1" ref-type="bibr">[23]</xref>. The intra-class correlation coefficient (ICC) of ADMA and TML was calculated using samples one year apart and subjects were considered as random effects (&#x0201c;oneway&#x0201d; model). Degree of correlation between covariates was assessed using Spearman&#x02019;s rank correlation coefficient.</p><p>In order to assess for non-linear relationships between outcome and explanatory variables, we first fitted a generalized additive mixed model (data not shown). A linear relationship provided the best model fit, thus we proceeded to use a simpler linear model.</p><p>As several lesions stemmed from the same patients &#x02013; i.e. 309 lesions from 183 patients, our data was not independent. We have previously addressed this problem using a mixed effects model allowing for random effects. <xref rid="pone.0064774-Lland1" ref-type="bibr">[5]</xref>.</p><p>Because of non-normal distributions we used a non-parametric test, i.e. conditional quantile regression (CQR). CQR is the estimation of an unknown quantile of an outcome as a function of a set of covariates where the response is assumed to follow an asymmetrical Laplace distribution and using a likelihood-based approach. <xref rid="pone.0064774-Geraci1" ref-type="bibr">[24]</xref> Bootstrapping is used to estimate the variance of the covariates.</p><p>We estimated the median DS as a function of fixed and random effects using a linear quantile mixed model (LQMM). A total of three models were fitted, i.e. two bivariate models with baseline measurement of ADMA or TML and DS as explanatory variables and a multivariate model which in addition included baseline measurements of age, gender, FA/B<sub>12</sub> intervention status (yes/no), follow-up time (days), diabetes (yes/no), current smoking (yes/no), systolic blood pressure (mmHg), body mass index (kg/m<sup>2</sup>), eGFR (mL/min/1.73 m<sup>2</sup>), apolipoprotein B100 (g/L) and C-reactive protein (mg/L). Estimation of the 10<sup>th</sup>, 25<sup>th</sup>, 50<sup>th</sup> (median), 75<sup>th</sup> and 90<sup>th</sup> percentile was performed for all models.</p><p>Using a similar LQMM, we assessed the effect of FA/vitamin B<sub>12</sub> supplementation on measurements of ADMA or TML at follow-up as outcome variable and ADMA or TML at baseline and FA/vitamin B<sub>12</sub> randomization status as explanatory variables. The clustering of coronary segments within lesions was the random effect.</p><p>LQMM was applied using the <italic>lqmm</italic> package <xref rid="pone.0064774-Geraci2" ref-type="bibr">[25]</xref> in <italic>R</italic> version 2.15.0 (R Development Core Team; Vienna, Austria), implemented as described by Geraci and Bottai. <xref rid="pone.0064774-Geraci1" ref-type="bibr">[24]</xref> Intra-class correlation coefficients were calculated using the R package, <italic>irr</italic> version 0.84. For all analyses, a p-value &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Baseline Characteristics</title><p>Baseline demographic, clinical and laboratory characteristics (<xref ref-type="table" rid="pone-0064774-t001">Table 1</xref>) showed higher systolic blood pressure, more extracardial disease as well as less statin and betablocker use in the B6/placebo group. Ninety-eight percent of the patients were treated with statins. Median (interquartile range [IQR]) age was 60.0 (14.0) years, 15.8% were women and 27.3% of the patients had a history of prior myocardial infarction. Median (IQR) serum total cholesterol was 5.0 (1.3) mmol/L, serum triglycerides 1.54 (0.87) mmol/L and serum CRP 2.0 (4.9) g/L. The median (IQR) concentrations were 0.51 (0.11) &#x000b5;mol/L for ADMA, 0.86 (0.36) &#x000b5;mol/L for TML and 10.3 (6.0) nmol/L for folate.</p><table-wrap id="pone-0064774-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064774.t001</object-id><label>Table 1</label><caption><title>Baseline Characteristics and Laboratory Findings in Patients with Angiographic Coronary Lesions (n&#x0200a;=&#x0200a;183).</title></caption><alternatives><graphic id="pone-0064774-t001-1" xlink:href="pone.0064774.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Characteristics</td><td align="left" rowspan="1" colspan="1">Group 1 (n&#x0200a;=&#x0200a;98)FA, B<sub>12</sub>&#x000b1;B<sub>6</sub>
</td><td align="left" rowspan="1" colspan="1">Group 2 (n&#x0200a;=&#x0200a;85)Placebo or B<sub>6</sub>
</td><td align="left" rowspan="1" colspan="1">P-value</td></tr></thead><tbody><tr><td colspan="2" align="left" rowspan="1">
<bold>Demographic characteristics</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Age - years</td><td align="left" rowspan="1" colspan="1">59.3 (10.5)</td><td align="left" rowspan="1" colspan="1">61.5 (9.4)</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Female sex - no. (%)</td><td align="left" rowspan="1" colspan="1">17 (17.3)</td><td align="left" rowspan="1" colspan="1">12 (14.1)</td><td align="left" rowspan="1" colspan="1">0.69</td></tr><tr><td colspan="2" align="left" rowspan="1">
<bold>Clinical characteristics</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Systolic Blood Pressure - mmHg</td><td align="left" rowspan="1" colspan="1">138.3 (20.7)</td><td align="left" rowspan="1" colspan="1">147.4 (23.9)</td><td align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Body Mass Index - m<sup>2</sup>/kg</td><td align="left" rowspan="1" colspan="1">27.0 (3.2)</td><td align="left" rowspan="1" colspan="1">27.2 (3.5)</td><td align="left" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ejection Fraction - %<xref ref-type="table-fn" rid="nt102">a</xref>
</td><td align="left" rowspan="1" colspan="1">60.7 (7.4)</td><td align="left" rowspan="1" colspan="1">61.6 (9.2)</td><td align="left" rowspan="1" colspan="1">0.45</td></tr><tr><td colspan="2" align="left" rowspan="1">
<bold>Cardiovascular risk factors - no. (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Stable angina at baseline angiography</td><td align="left" rowspan="1" colspan="1">67 (68.4)</td><td align="left" rowspan="1" colspan="1">59 (69.4)</td><td align="left" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NSTACS at presentation</td><td align="left" rowspan="1" colspan="1">31 (31.6)</td><td align="left" rowspan="1" colspan="1">26 (30.6)</td><td align="left" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Extracardial vascular disease<xref ref-type="table-fn" rid="nt103">b</xref>
</td><td align="left" rowspan="1" colspan="1">7 (7.1)</td><td align="left" rowspan="1" colspan="1">15 (17.6)</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Prior AMI</td><td align="left" rowspan="1" colspan="1">24 (24.5)</td><td align="left" rowspan="1" colspan="1">26 (30.6)</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Prior PCI</td><td align="left" rowspan="1" colspan="1">22 (22.4)</td><td align="left" rowspan="1" colspan="1">12 (14.1)</td><td align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Prior CABG</td><td align="left" rowspan="1" colspan="1">5 (5.1)</td><td align="left" rowspan="1" colspan="1">1 (1.2)</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hypercholesterolaemia</td><td align="left" rowspan="1" colspan="1">58 (59.2)</td><td align="left" rowspan="1" colspan="1">58 (68.2)</td><td align="left" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">40 (40.8)</td><td align="left" rowspan="1" colspan="1">40 (57.6)</td><td align="left" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Diabetes Mellitus (type I and II)</td><td align="left" rowspan="1" colspan="1">7 (7.1)</td><td align="left" rowspan="1" colspan="1">10 (11.8)</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Current smoker</td><td align="left" rowspan="1" colspan="1">34 (34.7)</td><td align="left" rowspan="1" colspan="1">27 (31.8)</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Disease severity</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;1-vessel disease</italic>
</td><td align="left" rowspan="1" colspan="1">36 (36.7)</td><td align="left" rowspan="1" colspan="1">31 (36.5)</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;2-vessel disease</italic>
</td><td align="left" rowspan="1" colspan="1">41 (41.8)</td><td align="left" rowspan="1" colspan="1">38 (44.7)</td><td align="left" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;3-vessel disease</italic>
</td><td align="left" rowspan="1" colspan="1">21 (21.4)</td><td align="left" rowspan="1" colspan="1">16 (18.8)</td><td align="left" rowspan="1" colspan="1">0.71</td></tr><tr><td colspan="2" align="left" rowspan="1">
<bold>Medical therapy</bold>
<xref ref-type="table-fn" rid="nt104">c</xref>
<bold>- no. (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Statins</td><td align="left" rowspan="1" colspan="1">98 (100.0)</td><td align="left" rowspan="1" colspan="1">81 (95.2)</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x003b2;-adrenergic receptor antagonists</td><td align="left" rowspan="1" colspan="1">82 (83.7)</td><td align="left" rowspan="1" colspan="1">57 (67.0)</td><td align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Calcium antagonists</td><td align="left" rowspan="1" colspan="1">18 (18.4)</td><td align="left" rowspan="1" colspan="1">11 (12.9)</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ACE-inhibitors<xref ref-type="table-fn" rid="nt105">d</xref>
</td><td align="left" rowspan="1" colspan="1">12 (12.2)</td><td align="left" rowspan="1" colspan="1">19 (22.4)</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Acetylsalisylic acid</td><td align="left" rowspan="1" colspan="1">96 (98.0)</td><td align="left" rowspan="1" colspan="1">85 (100.0)</td><td align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADP receptor antagonists</td><td align="left" rowspan="1" colspan="1">92 (93.9)</td><td align="left" rowspan="1" colspan="1">79 (92.9)</td><td align="left" rowspan="1" colspan="1">0.80</td></tr><tr><td colspan="2" align="left" rowspan="1">
<bold>Laboratory findings</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">S-C-Reactive Protein - mg/L</td><td align="left" rowspan="1" colspan="1">1.8 (4.9)</td><td align="left" rowspan="1" colspan="1">2.5 (4.9)</td><td align="left" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">S-LDL cholesterol - mmol/L</td><td align="left" rowspan="1" colspan="1">3.0 (1.3)</td><td align="left" rowspan="1" colspan="1">3.1 (1.1)</td><td align="left" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">S-HDL cholesterol - mmol/L</td><td align="left" rowspan="1" colspan="1">1.2 (0.4)</td><td align="left" rowspan="1" colspan="1">1.2 (0.4)</td><td align="left" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Apolipoprotein B100 - g/L</td><td align="left" rowspan="1" colspan="1">0.87 (0.34)</td><td align="left" rowspan="1" colspan="1">0.88 (0.28)</td><td align="left" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">eGFR &#x02013; mL/min/1.73 m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">95 (17)</td><td align="left" rowspan="1" colspan="1">93 (19)</td><td align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Serum glucose - mmol/L</td><td align="left" rowspan="1" colspan="1">5.5 (1.3)</td><td align="left" rowspan="1" colspan="1">5.7 (1.7)</td><td align="left" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Plasma -homocysteine - &#x000b5;mol/L</td><td align="left" rowspan="1" colspan="1">9.9 (3.1)</td><td align="left" rowspan="1" colspan="1">9.8 (3.3)</td><td align="left" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Plasma folate - nmol/L</td><td align="left" rowspan="1" colspan="1">10.1 (5.8)</td><td align="left" rowspan="1" colspan="1">11.0 (6.3)</td><td align="left" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Asymmetric dimethylarginine - &#x000b5;mol/L</td><td align="left" rowspan="1" colspan="1">0.50 (0.09</td><td align="left" rowspan="1" colspan="1">0.52 (0.12)</td><td align="left" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">S-Trimethyllysine - &#x000b5;mol/L</td><td align="left" rowspan="1" colspan="1">0.85 (0.34)</td><td align="left" rowspan="1" colspan="1">0.87 (0.40)</td><td align="left" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Carnitine &#x02013; &#x000b5;mol/L</td><td align="left" rowspan="1" colspan="1">40.5 (7.5)</td><td align="left" rowspan="1" colspan="1">41.0 (10.1)</td><td align="left" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x003b3;-Butyrobetaine &#x02013; &#x000b5;mol/L</td><td align="left" rowspan="1" colspan="1">0.98 (0.30)</td><td align="left" rowspan="1" colspan="1">1.02 (0.28)</td><td align="left" rowspan="1" colspan="1">0.05</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><p>For continuous variables, mean and standard deviation or median and interquartile range within each group is calculated. Student's T-test or Mann-Withney U-test was used to compare the two groups. For categorical variables, number and percentage is presentend and a Chi square test was used to compare the four groups. Fisher's exact test was used when appropriate. All biochemical parameteres are prestented as median (interquartile range). FA, folic acid (0.8 mg); B<sub>12</sub>, vitamin B<sub>12</sub> (0.4 mg); B<sub>6</sub>, vitamin B<sub>6</sub> (40 mg); PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; NSTACS, composite syndrom consisting of acute coronary syndrome including both ST-elevated and non-ST-elevated myocardial infarction; AMI, acute myocardial infarction; CHD, coronary heart disease; LMS, left main stem; LAD, left anterior descending artery; CX, circumflex branch; RCA, right coronary artery; ACE, Angiotensin I converting enzyme; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; ADMA, asymmetric dimethylarginine. Percentages may not add up due to rounding of numbers.</p></fn><fn id="nt102"><label>a</label><p>Ejection fraction was measured during ventriculography for the majority of the patients. When this was not performed, ultrasonic echocardiography was used.</p></fn><fn id="nt103"><label>b</label><p>A prior diagnosis of any peripheral or cerebrovascular disease.</p></fn><fn id="nt104"><label>c</label><p>Medication at discharge.</p></fn><fn id="nt105"><label>d</label><p>Including ARB - angiotensin receptor blockers.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Angiographic Findings</title><p>A total of 309 coronary lesions from 183 patients were finally identified by both observers to comply with the criteria for DS analysis, and angiographic characteristics are shown in <xref ref-type="table" rid="pone-0064774-t002">table 2</xref>. We observed progression of CAD during follow-up as indicated by a statistically significant change in DS. Among 309 lesions median (95% CI) DS increased by 3.51 (2.26&#x02013;4.76) percentage points (p&#x0003c;0.0001).</p><table-wrap id="pone-0064774-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064774.t002</object-id><label>Table 2</label><caption><title>Baseline Angiographic Characteristics of the 309 Coronary Lesions (from n&#x0200a;=&#x0200a;183 patients).</title></caption><alternatives><graphic id="pone-0064774-t002-2" xlink:href="pone.0064774.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="2" align="left" rowspan="1">Characteristic</td><td align="left" rowspan="1" colspan="1">Group 1 (n&#x0200a;=&#x0200a;152)FA, B<sub>12</sub>&#x000b1;B<sub>6</sub>
</td><td align="left" rowspan="1" colspan="1">Group 2 (n&#x0200a;=&#x0200a;157)Placebo or B<sub>6</sub>
</td><td align="left" rowspan="1" colspan="1">P Value</td></tr></thead><tbody><tr><td colspan="2" align="left" rowspan="1">
<bold>Selection - no. (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Included coronary lesions</td><td align="left" rowspan="1" colspan="1">152 (49.2)</td><td align="left" rowspan="1" colspan="1">157 (50.8)</td><td align="left" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Patients</td><td align="left" rowspan="1" colspan="1">98 (53.6)</td><td align="left" rowspan="1" colspan="1">85 (46.4)</td><td align="left" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">LMS lesions</td><td align="left" rowspan="1" colspan="1">2 (1.3)</td><td align="left" rowspan="1" colspan="1">1 (0.6)</td><td align="left" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">LAD lesions</td><td align="left" rowspan="1" colspan="1">38 (25.0)</td><td align="left" rowspan="1" colspan="1">31 (19.7)</td><td align="left" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CX lesions</td><td align="left" rowspan="1" colspan="1">34 (22.4)</td><td align="left" rowspan="1" colspan="1">48 (30.6)</td><td align="left" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">RCA lesions</td><td align="left" rowspan="1" colspan="1">78 (51.3)</td><td align="left" rowspan="1" colspan="1">77 (49.0)</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Analysed segment morphology</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Length analysed segment - mm</td><td align="left" rowspan="1" colspan="1">21.0 (7.2)</td><td align="left" rowspan="1" colspan="1">21.4 (6.5)</td><td align="left" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Length stenotic segment - mm</td><td align="left" rowspan="1" colspan="1">10.2 (4.2)</td><td align="left" rowspan="1" colspan="1">10.1 (4.3)</td><td align="left" rowspan="1" colspan="1">0.80</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reference diamenter - mm</td><td align="left" rowspan="1" colspan="1">3.09 (0.82)</td><td align="left" rowspan="1" colspan="1">3.08 (0.69)</td><td align="left" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Minimum lumen area - mm<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">4.16 (2.76)</td><td align="left" rowspan="1" colspan="1">3.95 (2.26)</td><td align="left" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Volume stenosis - mm<sup>3</sup>
</td><td align="left" rowspan="1" colspan="1">29.3 (11.9)</td><td align="left" rowspan="1" colspan="1">29.9 (11.9)</td><td align="left" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Minimum lumen diameter - mm</td><td align="left" rowspan="1" colspan="1">1.94 (0.61)</td><td align="left" rowspan="1" colspan="1">1.90 (0.49)</td><td align="left" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Diamenter stenosis - %</td><td align="left" rowspan="1" colspan="1">37.2 (9.7)</td><td align="left" rowspan="1" colspan="1">38.0 (9.6)</td><td align="left" rowspan="1" colspan="1">0.47</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt106"><p>For continuous variables, mean and standard deviation within each group is calculated. Student's T-test was used to compare the two groups. For categorical variables, number and percentage is presentend and a Chi square test used to compare the two groups. Fisher's exact test was used when appropriate. ). FA, folic acid (0.8 mg); B<sub>12</sub>, vitamin B<sub>12</sub> (0.4 mg); B<sub>6</sub>, vitamin B<sub>6</sub> (40 mg); LMS, left main stem artery; LAD, left anterior descending artery; CX; circumflex artery; RCA, right coronary artery; mm, millimeters.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Angiographic Progression According to Plasma Asymmetric Dimethylarginine and Trimethyllysine</title><p>The main results are shown in <xref ref-type="table" rid="pone-0064774-t003">table 3</xref> as well as <xref ref-type="fig" rid="pone-0064774-g001">figure 1</xref>. Plasma levels of ADMA at baseline were, in the bivariate model, significantly related to DS at follow-up. Median (95% CI) DS increased by 14.57 (1.79&#x02013;27.35) percentage points per &#x000b5;mol/L increase of ADMA (p-value 0.026). A similar statistically significant effect was found in the 25<sup>th</sup> percentile of DS, while in the 10<sup>th</sup>, 75<sup>th</sup> and 90<sup>th</sup> percentile of DS there was non-significant relation to ADMA.</p><fig id="pone-0064774-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064774.g001</object-id><label>Figure 1</label><caption><title>Asymmetric dimethylarginine, trimethyllysine and angiographic progression of coronary artery disease.</title><p>The graph shows the regression line from a linear quantile mixed model. The two left panels show the relation between the asymmetric dimethylarginine (ADMA) and DS measured at follow-up, whereas the two right panels show the relation between trimethyllysine (TML) and DS at follow-up. The bivariate models (adjusted for baseline DS measurement) are on the top and the multivariate (adjusted for age, sex, folic acid/B<sub>12</sub> intervention status, follow-up time, diabetes, smoking, systolic blood pressure, body mass index, estimated glomerular filtration rate (eGFR), apolipoprotein B100, C-reactive protein, ADMA or TML) at the bottom. The plasma level of either ADMA or TML is shown on the x-axis, with DS at follow-up on the y-axis. The solid line represents the regression line for the effect on median DS, while the others are displayed according to the legend.</p></caption><graphic xlink:href="pone.0064774.g001"/></fig><table-wrap id="pone-0064774-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064774.t003</object-id><label>Table 3</label><caption><title>Diameter stenosis at follow-up according to plasma concentrations of asymmetric dimethylarginine and trimethyllysine<xref ref-type="table-fn" rid="nt108">a</xref>.</title></caption><alternatives><graphic id="pone-0064774-t003-3" xlink:href="pone.0064774.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Independentvariable</td><td colspan="11" align="left" rowspan="1">Effect estimates for each variable according to modeled percentile of diameter stenosis at follow-up<xref ref-type="table-fn" rid="nt109">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">10<sup>th</sup> (31.5% DS)</td><td colspan="2" align="left" rowspan="1">25<sup>th</sup> (35.0% DS)</td><td colspan="2" align="left" rowspan="1">Median [50<sup>th</sup>](40.0% DS)</td><td colspan="2" align="left" rowspan="1">75<sup>th</sup> (47.0% DS)</td><td colspan="3" align="left" rowspan="1">90<sup>th</sup> (55.5% DS)</td></tr></thead><tbody><tr><td colspan="12" align="left" rowspan="1">
<italic>Bivariate ADMA model</italic>
<xref ref-type="table-fn" rid="nt110">c</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ADMA at baseline -&#x000b5;mol/L</td><td align="left" rowspan="1" colspan="1">9.63 (&#x02212;5.92&#x02013;25.19)</td><td align="left" rowspan="1" colspan="1">0.22</td><td align="left" rowspan="1" colspan="1">14.63 (0.94&#x02013;28.32)</td><td align="left" rowspan="1" colspan="1">0.04</td><td align="left" rowspan="1" colspan="1">14.57 (1.79&#x02013;17.35)</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">1.81 (&#x02212;15.77&#x02013;19.40)</td><td align="left" rowspan="1" colspan="1">0.84</td><td align="left" rowspan="1" colspan="1">5.04 (&#x02212;22.12&#x02013;32.19)</td><td colspan="2" align="left" rowspan="1">0.71</td></tr><tr><td colspan="12" align="left" rowspan="1">
<italic>Bivariate TML model</italic>
<xref ref-type="table-fn" rid="nt111">d</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TML at baseline -&#x000b5;mol/L</td><td align="left" rowspan="1" colspan="1">3.11 (0.64&#x02013;5.58)</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">2.19 (&#x02212;0.22&#x02013;4.60)</td><td align="left" rowspan="1" colspan="1">0.07</td><td align="left" rowspan="1" colspan="1">1.68 (&#x02212;0.15&#x02013;3.52)</td><td align="left" rowspan="1" colspan="1">0.07</td><td align="left" rowspan="1" colspan="1">1.00 (&#x02212;2.35&#x02013;4.34)</td><td align="left" rowspan="1" colspan="1">0.56</td><td align="left" rowspan="1" colspan="1">0.78 (&#x02212;4.32&#x02013;5.89)</td><td colspan="2" align="left" rowspan="1">0.76</td></tr><tr><td colspan="12" align="left" rowspan="1">
<italic>Multivariate mode</italic>
<xref ref-type="table-fn" rid="nt112">e</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ADMA &#x02013; &#x000b5;mol/L</td><td align="left" rowspan="1" colspan="1">24.25 (7.40&#x02013;41.10)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">19.75 (5.76&#x02013;33.74)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">18.35 (5.22&#x02013;31.49)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">19.93 (5.14&#x02013;34.73)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">22.07 (6.50&#x02013;37.65)</td><td colspan="2" align="left" rowspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">TML &#x02013; &#x000b5;mol/L</td><td align="left" rowspan="1" colspan="1">1.81 (&#x02212;0.99&#x02013;4.61)</td><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">1.73 (&#x02212;0.74&#x02013;4.20)</td><td align="left" rowspan="1" colspan="1">0.17</td><td align="left" rowspan="1" colspan="1">2.47 (0.37&#x02013;4.58)</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">2.09 (&#x02212;0.69&#x02013;4.87)</td><td align="left" rowspan="1" colspan="1">0.14</td><td align="left" rowspan="1" colspan="1">2.72 (&#x02212;1.12&#x02013;6.55)</td><td colspan="2" align="left" rowspan="1">0.16</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt107"><p>DS, Diameter Stenosis; ADMA, asymmetric dimethylarginine; TML, trimethyllysine.</p></fn><fn id="nt108"><label>a</label><p>Non-parametric linear quantile mixed-effects models of diameter stenosis at follow-up using Laplace distribution.</p></fn><fn id="nt109"><label>b</label><p>Effect estimate given as regression coefficient (95% confidence interval) and p-value for change in percentage point diameter stenosis.</p></fn><fn id="nt110"><label>c</label><p>The fixed effect in this model is ADMA and DS measured at baseline while the random effect is the clustering of arterial segments within a single patient. Estimates are presented as median (95% confidence interval). Standard error is estimated using bootstrapping.</p></fn><fn id="nt111"><label>d</label><p>The fixed effect in this model is TML and DS measured at baseline while the random effect is the clustering of arterial segments within a single patient. Estimates are presented as median (95% confidence interval). Standard error is estimated using bootstrapping.</p></fn><fn id="nt112"><label>e</label><p>The fixed effect in this model is DS measured at baseline, follow-up time in days, presence of diabetes, randomization (folic acid/B<sub>12</sub> vs no folic acid/B<sub>12</sub>) status at baseline, plasma TML at baseline, smoking status, age, gender, plasma ADMA at baseline, systolic blood pressure, body mass index, kidney function, apolioprotein B100 and C-reactive protein while the random effect is the clustering of arterial segments within a single patient. Standard error is estimated using bootstrapping.</p></fn></table-wrap-foot></table-wrap><p>Plasma TML at baseline was statistically significantly related to DS at follow-up in the bivariate model at the 10<sup>th</sup> percentile of DS, which increased by 3.11 (0.64&#x02013;5.58) percentage point per &#x000b5;mol/L increase of TML (p-value 0.01). At the 25<sup>th</sup>, median, 75<sup>th</sup> and 90<sup>th</sup> percentile of DS there was non-significant relation to TML.</p><p>In the multivariate model both ADMA and TML at baseline was independently associated with DS at follow-up (<xref ref-type="table" rid="pone-0064774-t003">Table 3</xref>). The median DS increased by 18.35 (5.22&#x02013;31.49) percentage points per &#x000b5;mol/L increase of ADMA (p-value 0.006) and 2.47 (0.37&#x02013;4.58) percentage points per &#x000b5;mol/L increase of TML (p-value 0.021). ADMA was significantly related to the 10<sup>th</sup>, 25<sup>th</sup>, 75<sup>th</sup> and 90<sup>th</sup> percentile of DS, while TML was not. In addition, male gender, C-reactive protein and eGFR were significantly related to DS.</p><p>Inclusion of eGFR in the multivariate model increased both the estimates and level of significance for both ADMA and TML regarding estimation of DS. When adjusting for &#x003b3;-butyrobetaine or carnitine in the multivariate model, no significant change to the ADMA or TML estimates or levels of significance occurred (data not shown). In separate analyses without inclusion of ADMA or TML, neither &#x003b3;-butyrobetaine nor carnitine predicted DS in bi- or multivariate analysis.</p><p>At baseline, the mean (SD) length of the included lesions was 21.2 (6.8) mm with a reference diameter of 3.08 (0.75) mm, minimum lumen diameter 1.92 (0.55) mm while DS was 37.6 (9.6) %.</p></sec><sec id="s3d"><title>Assessment of Correlation between Covariates</title><p>At baseline Spearman&#x02019;s ranks correlation coefficient between ADMA and TML was 0.27 (p-value &#x0003c;0.0001). ADMA showed the following correlation coefficients with other covariates: &#x003b3;-butyrobetaine 0.29 (p-value &#x0003c;0.0001), carnitine 0.08 (p-value 0.15), creatinine 0.17 (p-value 0.003) and eGFR &#x02212;0.35 (p-value &#x0003c;0.0001). TML significantly correlated (all p-value &#x0003c;0.0001) with &#x003b3;-butyrobetaine, carnitine, creatinine and eGFR with a correlation coefficient of 0.41, 0.22, 0.28 and &#x02212;0.26 respectively.</p><p>In addition, &#x003b3;-butyrobetaine correlated with carnitine 0.42 (p-value &#x0003c;0.0001), eGFR 0.42 (p-value &#x0003c;0.0001) and creatinine 0.54 (p-value &#x0003c;0.0001). Carnitine did not significantly correlate with eGFR (0.08; p-value 0.14) or creatinine (0.01; p-value 0.80).</p></sec><sec id="s3e"><title>Asymmetric Dimethylarginine and Trimethyllysine According to B Vitamin Supplementation</title><p>Cumulative distribution frequency plots showing the differences in ADMA and TML between baseline and follow-up during the B-vitamin treatment are shown in <xref ref-type="fig" rid="pone-0064774-g002">figure 2</xref> for both intervention groups. By visual inspection there was no apparent difference between baseline and follow-up measurements of neither ADMA nor TML levels between the two treatment groups. In LQMM, FA/vitamin B<sub>12</sub> treatment did not result in a statistically significant change in ADMA levels for the 25<sup>th</sup>, median, 75<sup>th</sup> or 90<sup>th</sup> percentile. The 10<sup>th</sup> percentile of ADMA did however increase with 0.040 (0.002&#x02013;0.078) &#x000b5;mol/L in patients receiving FA/vitamin B<sub>12</sub> (p-value 0.04). No percentile (10<sup>th</sup>, 25<sup>th</sup>, median, 75<sup>th</sup> or 90<sup>th</sup>) of TML was altered by FA/vitamin B<sub>12</sub> treatment. Vitamin B<sub>6</sub> treatment did not alter either ADMA or TML levels (data not shown).</p><fig id="pone-0064774-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064774.g002</object-id><label>Figure 2</label><caption><title>Asymmetric dimethylarginine and trimethyllysine before and after supplementation with folic acid/vitamin B<sub>12</sub>.</title><p>The graph shows empirical cumulative distribution frequencies for asymmetric dimethylarginine on the left and trimethyllysine on the right. Patients receiving folic acid/B<sub>12</sub> are displayed on the top, while patients receiving placebo or B<sub>6</sub> on the bottom. Time of measurement is shown as baseline (solid line) and follow-up (dashed line) after a median of 10.5 month.</p></caption><graphic xlink:href="pone.0064774.g002"/></fig></sec><sec id="s3f"><title>Intra-individual Stability of Biomarkers</title><p>Repeated measurements of ADMA and TML were available. One-way intra-class correlation coefficient (ICC) was 0.54 (95% CI 0.43&#x02013;0.64) for ADMA and 0.37 (95% CI 0.24&#x02013;0.49) for TML.</p></sec><sec id="s3g"><title>Patient Follow-up</title><p>Patients were followed for median (IQR) 316 (78) days. At sub-study end, patients assigned to FA/vitamin B<sub>12</sub> had lowered homocysteine levels by 24.8% whereas patients receiving vitamin B<sub>6</sub> alone or placebo had unchanged homocysteine levels compared to baseline).</p></sec></sec><sec id="s4"><title>Discussion</title><p>In the current substudy of a large randomized clinical trial with moderate doses of oral FA and vitamin B<sub>12</sub> we followed 183 patients treated with PCI for angiographic progression of CAD in non-treated lesions for a median of 10.5 months. A total of 309 coronary artery lesions as well as plasma levels of ADMA and TML were evaluated at both baseline and follow-up. Baseline levels of ADMA and TML was however independently associated with angiographic progression of CAD as measured by DS at follow-up in multivariate statistical models, with ADMA showing the strongest relationship. FA/vitamin B<sub>12</sub> supplementation did not alter median ADMA or TML at follow-up.</p><p>In accordance with previous studies we found ADMA to be associated with increased risk of CVD, <xref rid="pone.0064774-Cooke1" ref-type="bibr">[11]</xref>&#x02013;<xref rid="pone.0064774-Bger1" ref-type="bibr">[14]</xref> an effect mainly thought to be mediated through inhibition of NOS and subsequent endothelial dysfunction. <xref rid="pone.0064774-Cooke1" ref-type="bibr">[11]</xref> ADMA was independently associated with angiographic progression of CAD over a wide distribution of DS using a multivariate model &#x02013; i.e. the adverse effect of elevated ADMA was similar in respect to both the effect estimate and level of significance across the 10<sup>th</sup>, 25<sup>th</sup>, 50<sup>th</sup>, 75<sup>th</sup> and 90<sup>th</sup> percentile of DS. To our knowledge this association has not previously been shown for de novo atherosclerosis.</p><p>Like ADMA, TML is produced through post-translational methylation of amino acids in nuclear proteins <xref rid="pone.0064774-Strijbis1" ref-type="bibr">[16]</xref> and subsequent release through proteolysis; yet associations of TML with CVD have not been addressed. Both previous speculations <xref rid="pone.0064774-Loscalzo1" ref-type="bibr">[9]</xref> and emerging evidence <xref rid="pone.0064774-Handy1" ref-type="bibr">[6]</xref>, <xref rid="pone.0064774-Baccarelli1" ref-type="bibr">[26]</xref>, <xref rid="pone.0064774-Shirodkar1" ref-type="bibr">[27]</xref> suggest that epigenetic alterations of chromatin is relevant to the development and progression of atherosclerosis. Plasma levels of TML, in our material, were associated with angiographic progression of disease when we studied median DS in a multivariate model, but the effect was only borderline statistically significant in a bivariate model. In contrast to ADMA, TML levels is most likely dependent upon kidney function because TML availability is probably the rate-dependent step in carnitine biosynthesis, or at least TML clearance. <xref rid="pone.0064774-Bremer1" ref-type="bibr">[15]</xref>, <xref rid="pone.0064774-Zaspel1" ref-type="bibr">[28]</xref> Inclusion of eGFR in our multivariate models did however not substantially alter the TML effect; neither did inclusion of carnitine precursor &#x003b3;-butyrobetaine or carnitine, suggesting that the observed association between TML and CAD progression is not confounded by neither kidney function nor metabolites of carnitine biosynthesis. Accordingly, carnitine metabolites did not predict CAD progression in a separate analysis.</p><p>While the adverse CVD-consequence of ADMA has been linked to NO inhibition, there is no indication that TML acts by a similar mechanism. It is known that FA supplementation increases the availability of SAM and it has recently been shown that FA supplementation induces aberrant DNA methylation in vitro <xref rid="pone.0064774-Charles1" ref-type="bibr">[7]</xref> Increased SAM, induced by FA, may enhance methylation of histones, but data supporting such effects have not been published. Histone methylation can be either mono-, di- or trimethylated, all of which can alter gene expression. <xref rid="pone.0064774-Handy1" ref-type="bibr">[6]</xref> Since di- and trimethylated histones are precursors for ADMA and TML respectively, one could speculate if levels of ADMA and TML reflect global histone hypermethylation.</p><p>While we have previously reported a possible detrimental effect of FA treatment in a sub-group of patients, <xref rid="pone.0064774-Lland1" ref-type="bibr">[5]</xref> we were unable to prove an association between treatment with FA/vitamin B<sub>12</sub> and plasma levels of either TML or ADMA. Thus, this observation does not substantiate a possible relationship between histone hypermethylation and plasma levels ADMA or TML.</p><p>Because QCA is a lumenogram, it provides no coronary plaque information, for which intravascular ultrasound imaging or optical coherence tomography would be appropriate. However, QCA is considered an accurate method of measuring progression or regression of coronary atherosclerosis over time <xref rid="pone.0064774-Brown1" ref-type="bibr">[29]</xref> as well as being a reliable predictor of in-trial and post-trial clinical events <xref rid="pone.0064774-Azen1" ref-type="bibr">[18]</xref>, <xref rid="pone.0064774-Mack1" ref-type="bibr">[19]</xref>, <xref rid="pone.0064774-Waters1" ref-type="bibr">[30]</xref> and in some respect possibly superior to intravascular ultrasound imaging. <xref rid="pone.0064774-Berry1" ref-type="bibr">[31]</xref> Another limitation is the lack of data on global DNA or histone methylation status which makes us unable to conclude whether TML or ADMA reflect enhanced methylation during supplementation with FA. While FA has shown to induce DNA hypermethylation, <xref rid="pone.0064774-Charles1" ref-type="bibr">[7]</xref> effect on histone methylation following treatment with FA has not been reported.</p><p>Our study is amongst the larger studies using QCA <xref rid="pone.0064774-Azen1" ref-type="bibr">[18]</xref>, <xref rid="pone.0064774-Mack1" ref-type="bibr">[19]</xref>, <xref rid="pone.0064774-Douglas1" ref-type="bibr">[32]</xref>, <xref rid="pone.0064774-RodriguezGranillo1" ref-type="bibr">[33]</xref>. By performing all QCA analyses twice by 2 technicians and averaging the results, the precision of data analysis was increased. DS was chosen as the appropriate variable, since it, in contrast to minimum lumen diameter, is a relative measurement, thus reducing any potential calibration errors between the baseline and follow-up angiograms. In addition the statistical methods applied allow us to reduce the number of data assumptions. Mixed effects modeling was applied to adjust for the intra-patient correlation between coronary artery lesions, and quantile regression was used to enable non-parametric model allowing for untransformed data without having to assume normality; both methods leading to greater statistical robustness. <xref rid="pone.0064774-Geraci1" ref-type="bibr">[24]</xref> LQMM also allowed us to model the entire distribution of the outcome variable presenting a more total and unselected view of the data and illuminating any possible tail effects. <xref rid="pone.0064774-Rehkopf1" ref-type="bibr">[34]</xref> The modest ICCs of 0.37 for TML and 0.54 for ADMA, may be related to strict metabolic regulation <xref rid="pone.0064774-Teerlink1" ref-type="bibr">[35]</xref> and the influence of life-style factors such as diet and physical activity on plasma levels. Since risk estimates based single measurements tends to underestimate the true effect due to regression dilution one could suspect that the &#x0201c;true&#x0201d; relationships of ADMA and TML with DS are even stronger. <xref rid="pone.0064774-Clarke1" ref-type="bibr">[36]</xref>.</p><p>In this prospective study of patients with established CAD both ADMA and TML was significantly and independently associated with angiographic progression of CAD in multivariate statistical models, although with a slight asymmetrical effect for TML and with ADMA showing the strongest relationship. However, moderate doses of FA and vitamin B<sub>12</sub> did not alter the plasma levels of ADMA or TML except those in the lower 10<sup>th</sup> percentile of ADMA. Since degradation of methylated proteins such as histones is the sole source of TML and ADMA, one could speculate whether ADMA and TML are markers of global histone methylation. Further investigation should aim at identifying (lifestyle) determinants of plasma TML, effect on cardiovascular end-points and whether TML levels modify the effect of B-vitamin treatment.</p></sec></body><back><ack><p>We would especially like to thank Reinhard Seifert for statistical input and Torunn Eide for her analyses of TML, carnitine and &#x003b3;-butyrobetaine.</p></ack><ref-list><title>References</title><ref id="pone.0064774-Ebbing1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Ebbing</surname><given-names>M</given-names></name>, <name><surname>Bleie</surname><given-names>O</given-names></name>, <name><surname>Ueland</surname><given-names>PM</given-names></name>, <name><surname>Nordrehaug</surname><given-names>JE</given-names></name>, <name><surname>Nilsen</surname><given-names>DW</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography: A Randomized Controlled Trial</article-title>. <source>JAMA</source>
<volume>300</volume>: <fpage>795</fpage>&#x02013;<lpage>804</lpage>.<pub-id pub-id-type="pmid">18714059</pub-id></mixed-citation></ref><ref id="pone.0064774-Ebbing2"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Ebbing</surname><given-names>M</given-names></name>, <name><surname>B&#x000f8;naa</surname><given-names>KH</given-names></name>, <name><surname>Arnesen</surname><given-names>E</given-names></name>, <name><surname>Ueland</surname><given-names>PM</given-names></name>, <name><surname>Nordrehaug</surname><given-names>JE</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials</article-title>. <source>J Intern Med</source>
<volume>268</volume>: <fpage>367</fpage>&#x02013;<lpage>382</lpage>.<pub-id pub-id-type="pmid">20698927</pub-id></mixed-citation></ref><ref id="pone.0064774-Celik1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Celik</surname><given-names>T</given-names></name>, <name><surname>Iyisoy</surname><given-names>A</given-names></name>, <name><surname>Yuksel</surname><given-names>UC</given-names></name>, <name><surname>Isik</surname><given-names>E</given-names></name> (<year>2008</year>) <article-title>Homocysteine-lowering vitamins and cardiovascular mortality: Are they really effective?</article-title>
<source>Int J Cardiol</source>
<volume>128</volume>: <fpage>432</fpage>&#x02013;<lpage>433</lpage>.<pub-id pub-id-type="pmid">17689750</pub-id></mixed-citation></ref><ref id="pone.0064774-Ebbing3"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Ebbing</surname><given-names>M</given-names></name>, <name><surname>B&#x000f8;naa</surname><given-names>K</given-names></name>, <name><surname>Nyg&#x000e5;rd</surname><given-names>O</given-names></name>, <name><surname>Arnesen</surname><given-names>E</given-names></name>, <name><surname>Ueland</surname><given-names>PM</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Cancer incidence and mortality after treatment with folic acid and vitamin B12</article-title>. <source>JAMA</source>
<volume>302</volume>: <fpage>2119</fpage>&#x02013;<lpage>2126</lpage>.<pub-id pub-id-type="pmid">19920236</pub-id></mixed-citation></ref><ref id="pone.0064774-Lland1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>L&#x000f8;land</surname><given-names>KH</given-names></name>, <name><surname>Bleie</surname><given-names>&#x000d8;</given-names></name>, <name><surname>Blix</surname><given-names>AJ</given-names></name>, <name><surname>Strand</surname><given-names>E</given-names></name>, <name><surname>Ueland</surname><given-names>PM</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Effect of Homocysteine-Lowering B Vitamin Treatment on Angiographic Progression of Coronary Artery Disease: A Western Norway B Vitamin Intervention Trial (WENBIT) Substudy</article-title>. <source>Am J Cardiol</source>
<volume>105</volume>: <fpage>1577</fpage>&#x02013;<lpage>1584</lpage>.<pub-id pub-id-type="pmid">20494665</pub-id></mixed-citation></ref><ref id="pone.0064774-Handy1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Handy</surname><given-names>DE</given-names></name>, <name><surname>Castro</surname><given-names>R</given-names></name>, <name><surname>Loscalzo</surname><given-names>J</given-names></name> (<year>2011</year>) <article-title>Epigenetic Modifications</article-title>. <source>Circulation</source>
<volume>123</volume>: <fpage>2145</fpage>&#x02013;<lpage>2156</lpage>.<pub-id pub-id-type="pmid">21576679</pub-id></mixed-citation></ref><ref id="pone.0064774-Charles1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Charles</surname><given-names>M</given-names></name>, <name><surname>Johnson</surname><given-names>I</given-names></name>, <name><surname>Belshaw</surname><given-names>N</given-names></name> (<year>2012</year>) <article-title>Supra-physiological folic acid concentrations induce aberrant DNA methylation in normal human cells in vitro</article-title>. <source>EPIGENETICS</source>
<volume>7</volume>: <fpage>689</fpage>&#x02013;<lpage>694</lpage>.<pub-id pub-id-type="pmid">22617627</pub-id></mixed-citation></ref><ref id="pone.0064774-Jung1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Jung</surname><given-names>AY</given-names></name>, <name><surname>Smulders</surname><given-names>Y</given-names></name>, <name><surname>Verhoef</surname><given-names>P</given-names></name>, <name><surname>Kok</surname><given-names>FJ</given-names></name>, <name><surname>Blom</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>No Effect of Folic Acid Supplementation on Global DNA Methylation in Men and Women with Moderately Elevated Homocysteine</article-title>. <source>PLoS ONE</source>
<volume>6</volume>: <fpage>e24976</fpage>.<pub-id pub-id-type="pmid">21966393</pub-id></mixed-citation></ref><ref id="pone.0064774-Loscalzo1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Loscalzo</surname><given-names>J</given-names></name> (<year>2006</year>) <article-title>Homocysteine Trials - Clear Outcomes for Complex Reasons</article-title>. <source>N Engl J Med</source>
<volume>354</volume>: <fpage>1629</fpage>&#x02013;<lpage>1632</lpage>.<pub-id pub-id-type="pmid">16531615</pub-id></mixed-citation></ref><ref id="pone.0064774-Cheung1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Cheung</surname><given-names>P</given-names></name>, <name><surname>Lau</surname><given-names>P</given-names></name> (<year>2005</year>) <article-title>Epigenetic Regulation by Histone Methylation and Histone Variants</article-title>. <source>Mol Endocrinol</source>
<volume>19</volume>: <fpage>563</fpage>&#x02013;<lpage>573</lpage>.<pub-id pub-id-type="pmid">15677708</pub-id></mixed-citation></ref><ref id="pone.0064774-Cooke1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Cooke</surname><given-names>JP</given-names></name> (<year>2004</year>) <article-title>Asymmetrical Dimethylarginine</article-title>. <source>Circulation</source>
<volume>109</volume>: <fpage>1813</fpage>&#x02013;<lpage>1818</lpage>.<pub-id pub-id-type="pmid">15096461</pub-id></mixed-citation></ref><ref id="pone.0064774-Valkonen1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Valkonen</surname><given-names>V-P</given-names></name>, <name><surname>P&#x000e4;iv&#x000e4;</surname><given-names>H</given-names></name>, <name><surname>Salonen</surname><given-names>JT</given-names></name>, <name><surname>Lakka</surname><given-names>TA</given-names></name>, <name><surname>Lehtim&#x000e4;ki</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine</article-title>. <source>Lancet</source>
<volume>358</volume>: <fpage>2127</fpage>&#x02013;<lpage>2128</lpage>.<pub-id pub-id-type="pmid">11784629</pub-id></mixed-citation></ref><ref id="pone.0064774-Schnabel1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Schnabel</surname><given-names>R</given-names></name>, <name><surname>Blankenberg</surname><given-names>S</given-names></name>, <name><surname>Lubos</surname><given-names>E</given-names></name>, <name><surname>Lackner</surname><given-names>KJ</given-names></name>, <name><surname>Rupprecht</surname><given-names>HJ</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease</article-title>. <source>Circ Res</source>
<volume>97</volume>: <fpage>e53</fpage>&#x02013;<lpage>e59</lpage>.<pub-id pub-id-type="pmid">16100045</pub-id></mixed-citation></ref><ref id="pone.0064774-Bger1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>B&#x000f6;ger</surname><given-names>RH</given-names></name>, <name><surname>Sullivan</surname><given-names>LM</given-names></name>, <name><surname>Schwedhelm</surname><given-names>E</given-names></name>, <name><surname>Wang</surname><given-names>TJ</given-names></name>, <name><surname>Maas</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community</article-title>. <source>Circulation</source>
<volume>119</volume>: <fpage>1592</fpage>&#x02013;<lpage>1600</lpage>.<pub-id pub-id-type="pmid">19289633</pub-id></mixed-citation></ref><ref id="pone.0064774-Bremer1"><label>15</label><mixed-citation publication-type="other">Bremer J (1983) Carnitine - Metabolism and Functions. Physiol Rev 63.</mixed-citation></ref><ref id="pone.0064774-Strijbis1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Strijbis</surname><given-names>K</given-names></name>, <name><surname>Vaz</surname><given-names>FM</given-names></name>, <name><surname>Distel</surname><given-names>B</given-names></name> (<year>2010</year>) <article-title>Enzymology of the carnitine biosynthesis pathway</article-title>. <source>IUBMB Life</source>
<volume>62</volume>: <fpage>357</fpage>&#x02013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">20306513</pub-id></mixed-citation></ref><ref id="pone.0064774-Austen1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Austen</surname><given-names>W</given-names></name>, <name><surname>Edwards</surname><given-names>J</given-names></name>, <name><surname>Frye</surname><given-names>R</given-names></name>, <name><surname>Gensini</surname><given-names>G</given-names></name>, <name><surname>Gott</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>1975</year>) <article-title>A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association</article-title>. <source>Circulation</source>
<volume>51</volume>: <fpage>5</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">1116248</pub-id></mixed-citation></ref><ref id="pone.0064774-Azen1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Azen</surname><given-names>SP</given-names></name>, <name><surname>Mack</surname><given-names>WJ</given-names></name>, <name><surname>Cashin-Hemphill</surname><given-names>L</given-names></name>, <name><surname>LaBree</surname><given-names>L</given-names></name>, <name><surname>Shircore</surname><given-names>AM</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>Progression of Coronary Artery Disease Predicts Clinical Coronary Events: Long-term Follow-up From the Cholesterol Lowering Atherosclerosis Study</article-title>. <source>Circulation</source>
<volume>93</volume>: <fpage>34</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">8616937</pub-id></mixed-citation></ref><ref id="pone.0064774-Mack1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Mack</surname><given-names>WJ</given-names></name>, <name><surname>Xiang</surname><given-names>M</given-names></name>, <name><surname>Selzer</surname><given-names>RH</given-names></name>, <name><surname>Hodis</surname><given-names>HN</given-names></name> (<year>2000</year>) <article-title>Serial quantitative coronary angiography and coronary events</article-title>. <source>Am Heart J</source>
<volume>139</volume>: <fpage>993</fpage>&#x02013;<lpage>999</lpage>.<pub-id pub-id-type="pmid">10827379</pub-id></mixed-citation></ref><ref id="pone.0064774-Bleie1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Bleie</surname><given-names>O</given-names></name>, <name><surname>Refsum</surname><given-names>H</given-names></name>, <name><surname>Ueland</surname><given-names>PM</given-names></name>, <name><surname>Vollset</surname><given-names>SE</given-names></name>, <name><surname>Guttormsen</surname><given-names>AB</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention</article-title>. <source>Am J Clin Nutr</source>
<volume>80</volume>: <fpage>641</fpage>&#x02013;<lpage>648</lpage>.<pub-id pub-id-type="pmid">15321804</pub-id></mixed-citation></ref><ref id="pone.0064774-Bjrndal1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Bj&#x000f8;rndal</surname><given-names>B</given-names></name>, <name><surname>Burri</surname><given-names>L</given-names></name>, <name><surname>Wergedahl</surname><given-names>H</given-names></name>, <name><surname>Svardal</surname><given-names>A</given-names></name>, <name><surname>Bohov</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Dietary supplementation of herring roe and milt enhances hepatic fatty acid catabolism in female mice transgenic for hTNF&#x003b1;</article-title>. <source>European Journal of Nutrition</source>
<volume>51</volume>: <fpage>741</fpage>&#x02013;<lpage>753</lpage>.<pub-id pub-id-type="pmid">21986673</pub-id></mixed-citation></ref><ref id="pone.0064774-Levey1"><label>22</label><mixed-citation publication-type="other">Levey AS, Greene T, Kusek JW, Beck GL, MDRD Study Group (2000) A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 11.</mixed-citation></ref><ref id="pone.0064774-Rothwell1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Rothwell</surname><given-names>PM</given-names></name> (<year>2000</year>) <article-title>Analysis of agreement between measurements of continuous variables: general principles and lessons from studies of imaging of carotid stenosis</article-title>. <source>J Neurol</source>
<volume>247</volume>: <fpage>825</fpage>&#x02013;<lpage>834</lpage>.<pub-id pub-id-type="pmid">11151413</pub-id></mixed-citation></ref><ref id="pone.0064774-Geraci1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Geraci</surname><given-names>M</given-names></name>, <name><surname>Bottai</surname><given-names>M</given-names></name> (<year>2007</year>) <article-title>Quantile regression for longitudinal data using the asymmetric Laplace distribution</article-title>. <source>Biostatistics</source>
<volume>8</volume>: <fpage>140</fpage>&#x02013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">16636139</pub-id></mixed-citation></ref><ref id="pone.0064774-Geraci2"><label>25</label><mixed-citation publication-type="other">Geraci M (2012) lqmm: Linear Quantile Mixed Models. R package version 1.01 ed.</mixed-citation></ref><ref id="pone.0064774-Baccarelli1"><label>26</label><mixed-citation publication-type="other">Baccarelli A, Ghosh S (2012) Environmental exposures, epigenetics and cardiovascular disease. Curr Opin Clin Nutr Metab Care 15: 323&#x02013;329 310.1097/MCO.1090b1013e328354bf328355c.</mixed-citation></ref><ref id="pone.0064774-Shirodkar1"><label>27</label><mixed-citation publication-type="other">Shirodkar AV, Marsden PA (2011) Epigenetics in cardiovascular disease. Curr Opin Cardiol 26: 209&#x02013;215 210.1097/HCO.1090b1013e328345986e.</mixed-citation></ref><ref id="pone.0064774-Zaspel1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Zaspel</surname><given-names>B</given-names></name>, <name><surname>Sheridan</surname><given-names>K</given-names></name>, <name><surname>Henderson</surname><given-names>L</given-names></name> (<year>1980</year>) <article-title>Transport and metabolism of carnitine precursors in various organs of the rat</article-title>. <source>Biochim Biophys Acta</source>
<volume>631</volume>: <fpage>192</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="pmid">6772237</pub-id></mixed-citation></ref><ref id="pone.0064774-Brown1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Brown</surname><given-names>BG</given-names></name> (<year>2007</year>) <article-title>A direct comparison of intravascular ultrasound and quantitative coronary arteriography: implications for measures of atherosclerosis as clinical surrogates</article-title>. <source>Circulation</source>
<volume>115</volume>: <fpage>1824</fpage>&#x02013;<lpage>1826</lpage>.<pub-id pub-id-type="pmid">17420360</pub-id></mixed-citation></ref><ref id="pone.0064774-Waters1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Waters</surname><given-names>D</given-names></name>, <name><surname>Craven</surname><given-names>T</given-names></name>, <name><surname>Lesp&#x000e9;rance</surname><given-names>J</given-names></name> (<year>1993</year>) <article-title>Prognostic significance of progression of coronary atherosclerosis</article-title>. <source>Circulation</source>
<volume>87</volume>: <fpage>1067</fpage>&#x02013;<lpage>1075</lpage>.<pub-id pub-id-type="pmid">8484829</pub-id></mixed-citation></ref><ref id="pone.0064774-Berry1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Berry</surname><given-names>C</given-names></name>, <name><surname>L'Allier</surname><given-names>PL</given-names></name>, <name><surname>Gregoire</surname><given-names>J</given-names></name>, <name><surname>Lesperance</surname><given-names>J</given-names></name>, <name><surname>Levesque</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Comparison of Intravascular Ultrasound and Quantitative Coronary Angiography for the Assessment of Coronary Artery Disease Progression</article-title>. <source>Circulation</source>
<volume>115</volume>: <fpage>1851</fpage>&#x02013;<lpage>1857</lpage>.<pub-id pub-id-type="pmid">17389269</pub-id></mixed-citation></ref><ref id="pone.0064774-Douglas1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Douglas</surname><given-names>JS</given-names><suffix>Jr</suffix></name>, <name><surname>Holmes</surname><given-names>DR</given-names><suffix>Jr</suffix></name>, <name><surname>Kereiakes</surname><given-names>DJ</given-names></name>, <name><surname>Grines</surname><given-names>CL</given-names></name>, <name><surname>Block</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Coronary Stent Restenosis in Patients Treated With Cilostazol</article-title>. <source>Circulation</source>
<volume>112</volume>: <fpage>2826</fpage>&#x02013;<lpage>2832</lpage>.<pub-id pub-id-type="pmid">16246948</pub-id></mixed-citation></ref><ref id="pone.0064774-RodriguezGranillo1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Rodriguez-Granillo</surname><given-names>GA</given-names></name>, <name><surname>Vos</surname><given-names>J</given-names></name>, <name><surname>Bruining</surname><given-names>N</given-names></name>, <name><surname>Garcia-Garcia</surname><given-names>HM</given-names></name>, <name><surname>de Winter</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Long-Term Effect of Perindopril on Coronary Atherosclerosis Progression (from the PERindopril's Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study)</article-title>. <source>Am J Cardiol</source>
<volume>100</volume>: <fpage>159</fpage>&#x02013;<lpage>163</lpage>.<pub-id pub-id-type="pmid">17631061</pub-id></mixed-citation></ref><ref id="pone.0064774-Rehkopf1"><label>34</label><mixed-citation publication-type="other">Rehkopf DH (2012) Commentary: Quantile Regression for Hypothesis Testing and Hypothesis Screening at the Dawn of Big Data. Epidemiology 23: 665&#x02013;667 610.1097/EDE.1090b1013e318261f318267be.</mixed-citation></ref><ref id="pone.0064774-Teerlink1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Teerlink</surname><given-names>T</given-names></name> (<year>2005</year>) <article-title>ADMA metabolism and clearance</article-title>. <source>Vasc Med</source>
<volume>10</volume>: <fpage>S73</fpage>&#x02013;<lpage>S81</lpage>.<pub-id pub-id-type="pmid">16444872</pub-id></mixed-citation></ref><ref id="pone.0064774-Clarke1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Clarke</surname><given-names>R</given-names></name>, <name><surname>Shipley</surname><given-names>M</given-names></name>, <name><surname>Lewington</surname><given-names>S</given-names></name>, <name><surname>Youngman</surname><given-names>L</given-names></name>, <name><surname>Collins</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Underestimation of Risk Associations Due to Regression Dilution in Long-term Follow-up of Prospective Studies</article-title>. <source>Am J Epidemiol</source>
<volume>150</volume>: <fpage>341</fpage>&#x02013;<lpage>353</lpage>.<pub-id pub-id-type="pmid">10453810</pub-id></mixed-citation></ref></ref-list></back></article>